- Home
- XTKG vs QNTM Comparison
XTKG vs QNTM Comparison
Compare XTKG & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- QNTM
- Stock Information
- Founded
- XTKG 1997
- QNTM 1998
- Country
- XTKG Singapore
- QNTM Canada
- Employees
- XTKG N/A
- QNTM N/A
- Industry
- XTKG
- QNTM
- Sector
- XTKG
- QNTM
- Exchange
- XTKG NYSE
- QNTM NYSE
- Market Cap
- XTKG 8.5M
- QNTM 8.7M
- IPO Year
- XTKG 2019
- QNTM N/A
- Fundamental
- Price
- XTKG $1.13
- QNTM $6.91
- Analyst Decision
- XTKG
- QNTM
- Analyst Count
- XTKG 0
- QNTM 0
- Target Price
- XTKG N/A
- QNTM N/A
- AVG Volume (30 Days)
- XTKG 95.6K
- QNTM 919.6K
- Earning Date
- XTKG 05-21-2025
- QNTM 05-06-2025
- Dividend Yield
- XTKG N/A
- QNTM N/A
- EPS Growth
- XTKG N/A
- QNTM N/A
- EPS
- XTKG N/A
- QNTM N/A
- Revenue
- XTKG $15,234,138.00
- QNTM N/A
- Revenue This Year
- XTKG N/A
- QNTM N/A
- Revenue Next Year
- XTKG N/A
- QNTM N/A
- P/E Ratio
- XTKG N/A
- QNTM N/A
- Revenue Growth
- XTKG 51.59
- QNTM N/A
- 52 Week Low
- XTKG $0.08
- QNTM $2.70
- 52 Week High
- XTKG $2.14
- QNTM $33.80
- Technical
- Relative Strength Index (RSI)
- XTKG 56.45
- QNTM 53.04
- Support Level
- XTKG $0.90
- QNTM $5.91
- Resistance Level
- XTKG $1.29
- QNTM $6.43
- Average True Range (ATR)
- XTKG 0.15
- QNTM 0.72
- MACD
- XTKG -0.02
- QNTM -0.05
- Stochastic Oscillator
- XTKG 53.70
- QNTM 56.19
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.